Human papillomavirus infection: a randomised controlled trial of Imiquimod cream (5%) versus Podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccination in the treatment and prevention of recurrence of anogenital warts (HIPvac Trial)

Trial Profile

Human papillomavirus infection: a randomised controlled trial of Imiquimod cream (5%) versus Podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccination in the treatment and prevention of recurrence of anogenital warts (HIPvac Trial)

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary) ; Imiquimod (Primary) ; Podophyllotoxin (Primary) ; Hepatitis A vaccine
  • Indications Genital warts; Human papillomavirus infections
  • Focus Therapeutic Use
  • Acronyms HIPvac
  • Most Recent Events

    • 03 Apr 2017 Status changed from recruiting to completed.
    • 17 Mar 2016 Accrual to date is 27% according to the United Kingdom Clinical Research Network record.
    • 11 Feb 2016 Accrual to date is 24% according to the United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top